Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

Drug Safety

Volumn 27, Issue 3, 2004, Pages 185-196

  Schmidt, Helmut ^a   Woodcock, Barry G ^a   Geisslinger, Gerd ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SELECTIVITY; DYSPEPSIA; DYSPNEA; EDEMA; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HEADACHE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; INSOMNIA; KIDNEY FUNCTION; LASSITUDE; MALAISE; MEDICAL ASSESSMENT; MIGRAINE; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN; PATIENT MONITORING; PERFORATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RASH; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH INJURY; ULCER; VOMITING;

CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LACTONES; OSTEOARTHRITIS; RISK ASSESSMENT; SULFONES;

EID: 1542285157     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427030-00003     Document Type: Review

References (71)

1. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other NSAIDs: a 6-week and a 1-year trial in patients with osteoarthritis: Osteoarthritis Studies Group. Arch Fam Med 2000 Nov-Dec; 9 (10): 1124-34
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of NSAIDs. N Engl J Med 1999 Jun 17; 340 (24): 1888-99
3. Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000 Mar; 85 (1-2): 169-82
4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971 Jun 23; 231 (25): 232-5
5. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995 Nov 3; 83 (3): 483-92
6. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000 Sep; 119 (3): 706-14
7. Wallace JL. NSAIDs and gastroenteropathy: the second hundred years. Gastroenterology 1997 Mar; 112 (3): 1000-16
8. Lipsky LP, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors. J Rheumatol 1998 Dec; 25 (12): 2298-303
9. Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by NSAIDs. J Physiol Pharmacol 1997 Dec; 48 (4): 623-31
10. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994 Dec; 271 (3): 1705-12
11. Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003 Jul; 55 (7): 859-94
12. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42 (6): 545-6
13. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis: Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000 Jun 26; 160 (12): 1781-7
14. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip: Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000 May; 43 (5): 978-87
15. Myllykangas-Luosujarvi R, Lu HS, Chen SL, et al. Comparison of low-dose rofecoxib versus 1000mg naproxen in patients with osteoarthritis: results of two randomized treatment trals of six weeks duration. Scand J Rheumatol 2002; 31 (6): 337-44
16. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002 Jan 2; 287 (1): 64-71
17. Theiler R, Bischoff HA, Good M, et al. Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. Swiss Med Wkly 2002 Nov 2; 132 (39-40): 566-73
18. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 Suppl. 1: 37-46
19. Arboleya LR, de la Figuera E, Soledad Garcia M, et al. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin 2003; 19 (4): 288-97
20. Collantes-Estevez E, Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003; 19 (5): 402-10
21. Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002; 18 (4): 229-36
22. Steinfeld S, Bjorke PA. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. Rheumatology (Oxford) 2002 Apr; 41 Suppl. 1: 23-7
23. Steinfeld S, Poriau S. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA survey. Curr Med Res Opin 2001; 17 (2): 81-7
24. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving NSAIDs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123 (4): 241-9
25. Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology 2001 Feb; 120 (3): 594-606
26. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8
27. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-55
28. Holt S, Rigoglioso V, Sidhu M, et al. NSAIDs and lower GI bleeding. Dig Dis Sci 1993 Sep; 38 (9): 1619-23
29. Wilcox CM, Alexander LN, Cotsonis GA, et al. NSAIDs are associated with both upper and lower GI bleeding. Dig Dis Sci 1997 May; 42 (5): 990-7
30. Laine L, Connors LG, Reicin A, et al. Serious lower GI clinical events with nonselective NSAID or coxib use. Gastroenterology 2003 Feb; 124 (2): 288-92
31. Micklewright R, Lane S, Linley W, et al. NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003 Feb; 17 (3): 321-32
32. Juni P, Sterchi R, Dieppe P. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis: problems compromise review's validity [letter]. BMJ 2003 Feb 8; 326 (7384): 334
33. Metcalfe S, Dougherty S, McNee W. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis: celecoxib's relative GI safety is overstated [letter]. BMJ 2003 Feb 8; 326 (7384): 334
34. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper GI safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 Sep 21; 325 (7365): 619-25
35. National Institute for Clinical Excellence (NICE). Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology Appraisal no. 27. National Institute for Clinical Excellence, London, 2001 [online]. Available from URL: www.nice.org.uk/cat.asp?c=18033 [Accessed 2004 Jan]
36. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper GI haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional NSAIDs. BMJ 2002 Sep 21; 325 (7365): 624-7
37. Layton D, Riley J, Wilton LV, et al. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2003 Feb; 55 (2): 166-74
38. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 Aug 9; 345 (6): 433-42
39. Wallberg-Jonsson S, Cederfelt M, RantapaaDahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000 Jan; 27 (1): 71-5
40. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997 Mar; 24 (3): 445-51
41. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987 Jan; 69 (1): 180-6
42. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22-29; 286 (8): 954-9
43. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 Dec 20; 345 (25): 1809-17
44. van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000 Oct; 40 (10): 1109-20
45. Ray WA, Stein CM, Hall K, et al. NSAIDs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002 Jan 12; 359 (9301): 118-23
46. Cleland JG. No reduction in cardiovascular risk with NSAIDs-including aspirin? Lancet 2002 Jan 12; 359 (9301): 92-3
47. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001 Mar-Apr; 8 (2): 85-95
48. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Drug Saf 2002; 25 (12): 829-35
49. Saito T, Rodger IW, Hu F, et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000 Jul 5; 273 (2): 772-5
50. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002 Aug 15; 47 (4): 349-55
51. Bannwarth B, Dougados M. Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib. J Rheumatol 2003 Feb; 30 (2): 421-2
52. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001 Nov 6; 104 (19): 2280-8
53. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003 Feb 24; 163 (4): 481-6
54. Layton D, Heeley E, Hughes K, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003 Nov; 42 (11): 1342-53. Epub 2003 Jun 27
55. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vase Biol 1999 Mar; 19 (3): 646-55
56. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999 Oct; 155 (4): 1281-91
57. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002 Oct; 13 (5): 497-504
58. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994 Dec; 94 (6): 2504-10
59. Lorenz JN, Greenberg SG, Briggs JP. The macula densa mechanism for control of renin secretion. Semin Nephrol 1993 Nov; 13 (6): 531-42
60. Harding P, Carretero OA, Beierwaltes WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens 2000 Aug; 18 (8): 1107-13
61. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987 Jul; 32 (1): 1-12
62. Gertz BJ, Krupa D, Bolognese JA, et al. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective NSAIDs. Curr Med Res Opin 2002; 18 (2): 82-91
63. Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25 (7): 537-44
64. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001 Dec; 38 (6): 1145-57
65. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001 Sep; 23 (9): 1478-91
66. Whelton A. Renal aspects of treatment with conventional NSAIDs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001 Feb 19; 110 Suppl. 3A: 33S-42S
67. Stillman MT, Schlesinger PA. NSAID nephrotoxicity: should we be concerned? Arch Intern Med 1990 Feb; 150 (2): 268-70
68. Bannwarth B, Treves R, Euller-Ziegler L, et al. Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. Drug Saf 2003; 26 (1): 49-54
69. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001 Oct; 15 (12): 2057-72
70. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 2001 Jul; 15 (9): 1622-4
71. Niederberger E, Tegeder I, Schafer C, et al. Opposite effects of rofecoxib on nuclear factor-κB and activating protein-1 activation. J Pharmacol Exp Ther 2003 Mar; 304 (3): 1153-60